Determining Vaccine Dosage with Fuzzy Logic in Allergen Immunotherapy for Allergic Asthma

Abstract

Inflammation and airway constriction, which restrict airflow, are the hallmarks of the CH. Inflammation and airway constriction are the hallmarks of the chronic respiratory disease asthma. When allergens and environmental elements cause this narrowing of the airways, allergic asthma develops. It may show signs including coughing, wheezing, and tightness in the chest. Simple controller medicines and bronchodilators are insufficient for severe instances of asthma. In such circumstances, allergen immunotherapy, commonly referred to as vaccination therapy, is one of the treatment alternatives. Allergen immunotherapy is a form of medicine that lessens a person's immunological reaction to allergens. Inflammation and airway constriction, which restrict airflow, are the hallmarks of the CH. Patients may experience local, systemic, or anaphylactic reactions following vaccination, though. Determining the dosage is crucial for patients who have systemic and anaphylactic reactions. The doctor uses their expertise and knowledge to lower or raise the dosage when modifications are required based on the patient's response. Additionally, doctors may find this role to be both significant and onerous. The optimal dosage can be established by conducting a fuzzy study based on the patient's pulmonary function test and post-vaccination reactions. With more precise data, the process may be advanced, and doctors' stress levels are to be reduced as a result of this study. The main objective is to reduce the adverse reactions that patients experience after vaccination in order to successfully complete the therapy and reduce, as much as possible, any adverse effects on the patient's life that may result from the vaccine.

Keywords

• fuzzy
• Asthma
• Allergen immunotherapy
• Determining vaccine dosage

Thanks

I would like to express my gratitude to the administration of Dr. Sami Ulus Women's Health, Child Health, and Diseases Training and Research Hospital and to the esteemed instructors working at the Pediatric Allergy Clinic for their unwavering support and attention during my treatment process, as well as for sharing their knowledge and experiences. I extend my heartfelt thanks to my family, who have always been by my side, never wavered in their support, believed in me, and provided both financial and moral support throughout my treatment journey. With the hope of practicing my profession in the light of knowledge, ethics, and secularism...

References

1. [1] M. Blaiss Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004;26(11):1876-1889.
2. [2] L. Tamer, M. Calikoğlu, NA. Ates, et al. Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respirology 2004;9(4):493-8.
3. [3] R. Pawankar, Allergic rhinitis and asthma: are they manifestations of one syndrome?. Clin Exp Allergy 2006;36(1):1-4.
4. [4] L. Söderström, A. Kober, S. Ahlstedt, et al. A further evaluation of the clinical use of specific IgE antibody testing in allergic diseases. Allergy. 2003;58(9):921-8.
5. [5] J. W. Yunginger, S Ahlstedt, PA Eggleston, et al. Quantitative IgE antibody assays in allergic diseases. J Allergy Clin Immunol 2000;105(6):1077-84.
6. [6] S. T. Holgate, Genetic and environmental interaction in allergy and asthma. J Allergy Clin Immunol 1999;104(6):1139-46.
7. [7] N. Mygind, R. Dahl, S. Pedersen, K. Thestruhp-Pedersen (eds). Allergy hand book Translate: Şirin A (edt). 1. Turgut 1988. 36-59.
8. [8] H. S. Nelson, Immunotherapy for inhalant allergens. In: Adkinson Jr NF, Bochner BS, Busse WW (eds). Middleton’s Allergy Principles and Practice. 7th edition. Philadelphia: Mosby Elsevier; 2009. 1657-77.

9. [9] L. Noon Prophylactic inoculation against hay fever. Lancet 1911;1:1572- 3.
10. [10] Ş. Çekiç, N. Sapan, Allergen Specific Immunotherapy. J Curr Pediatr 2015;13:46-55.
11. [11] Global Initiative For Asthma. Global Strategy for Asthma Management and Prevention. 2016.
12. [12] Ö. Abadoğlu, Asthma control assessment questionnaires. Asthma Allergy Immunol 2008;6:99-104.
13. [13] E. G. Oh. The relationship between disease control, Symptom distress, functioning, and quality of life in adults with asthma. J Asthma 2008;45:882-6.
14. [14] H. K. Reddel, LB. Bacharier, ED. Bateman et al. Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumologia 2022;58(1):35-51.
15. [15] F. D. Martinez, Development of wheezing disorders and asthma in preschool children. Pediatrics 2002;109(2)362-7.
16. [16] R. C. Strunk, Defining asthma in the preschool-aged child. Pediatrics 2002;109(2):357-61.
17. [17] A. Selçuk, O. Şener. part 16, Vaccine (Immunotherapy) Treatment in Allergy https://solunum.org.tr/TusadData/Book/327/1252015145833-17_Bolum_16_Asi.pdf
18. [18] A. Eggleston, M. D. Peyton, Allergen-specific immunotherapy in childhood asthma. Current Opinion in Pediatrics 9(6):s 582-584, Aralık 1997.